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Abstract 
BACKGROUND: Melanoma appears to be a malignant disease, whose development can be potentiated by 
different drug groups. More and more data are in favour of the claim that commonly used antihypertensive drugs 
also contain the risk of developing melanoma. The most evidence is that angiotensin receptor blockers may be 
carcinogenic. Two representatives from this group, valsartan and irbesartan, produced by certain pharmaceutical 
companies are being withdrawn from the market due to finding content of NDMA and NDEA, which are believed 
to be potent carcinogens. Another representative of this group, losartan, according to in vitro data, potentiates cell 
adhesion and invasion of human melanoma cells. 
CASE REPORT: We present a 45-year-old man with arterial hypertension. For year and a half/two years, the 
patient is on systemic therapy with Aspirin and Irbesartan/Hydrochlorothiazide. The patient also reported about 
the presence of a pigmented lesion in the abdominal area, which occurred 5-6 years ago, before the onset of 
cardiac therapy. According to him, there was a change in the colour and size of the lesion within the framework of 
cardiac therapy (from 1.5-2 years). Innovative one step melanoma surgery was performed, and the lesion was 
radically removed with a 1 cm operational safety margin in all directions within one operative session. The 
subsequent histological verification found the presence of thin melanoma. 
CONCLUSION: Drug-induced melanoma turned out to be a problem of significant importance. The group of 
angiotensin receptor blockers should be investigated more thoroughly and in detail on the probability of 
potentiating carcinogenesis. We describe an interesting case showing the progression of pigment lesion to 
melanoma as a possible result of irbesartan therapy, i.e. we share a theory that differs from that of drug-induced 
de novo melanomas. It should not be overlooked the fact that another widely used drug-Aspirin, is also likely to 
potentiate the development of melanoma. Furthermore, the case is indicative of the use of one step melanoma 
surgery in a melanoma patient with a thickness less than 1 mm. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
The number of studies, according to which 
different groups of antihypertensive drugs are likely to 
potentiate the development of melanoma, increases 
significantly [1], [2], [3]. According to the literature, 
angiotensin receptor blockers (ARBs), which are 
widely used as antihypertensive drugs, carry an 
increased risk of developing cancer [4]. The latest 
data suggest that the occurrence of cutaneous 
cancer, including cutaneous melanoma, is also 
associated with this group of drugs [2], [5]. 
Experimental in vitro data show that losartan (ARB) 
stimulates cell adhesion and invasion of human 
melanoma cells [3]. 
 
 
Case report 
 
We present a 45-year-old man in good 
general condition and concomitant arterial 
hypertension, controlled through medication with 
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Aspirin 100 mg (0-0-1) and Irbesartan/ 
Hydrochlorothiazide 150 mg/12.5 mg (1-0-0). The 
patient was hospitalised at the clinic on the occasion 
of worsening, for several months, of psoriasis vulgaris, 
diagnosed from 20 years. During the dermatological 
examination, despite the psoriatic skin changes, in the 
area of regio abdominalis dextra, was visualised as 
finding a hyperpigmented macula with uneven 
pigmentation and uneven edges (Figure 1a and 1b). 
According to the patient, the pigmented lesion 
appeared 5-6 years ago. Medication therapy with 
Aspirin and Irbesartan/Hydrochlorothiazide dates from 
1.5-2 years. According to anamnestic data, within the 
framework of cardiac therapy, the patient observed a 
change in the colour and size of the lesion. Clinically 
and dermatoscopically, the pigmented macula met the 
requirements for a malignant melanocytic lesion. Also, 
clinical and dermatoscopic data spoke in favour of 
melanoma less than 1 mm thick. Based on these data, 
one step melanoma surgery (OSMS) was performed. 
The lesion was removed by elliptical excision, under 
local anaesthesia, with a surgical field of 1 cm in all 
directions (Figure 1b and 1c). Тhe surgical defect was 
closed by a single interrupted sutures (Figure 1d). 
Histological examination confirmed the diagnosis: 
superficial malignant melanoma, Clark II level, 
Breslow’s thickness below 1 mm, no ulceration, low 
mitotic activity, well-expressed lymphocytic stromal 
reaction, clear resection lines. The staging was 
performed according to which it was found to be 
melanoma Stage I (T1aN0M0). 
 
Figure 1: a) Clinical picture of primary cutaneous melanoma located 
in regio abdominalis dextra with uneven pigmentation; b) Outlining 
the 1 cm operational security boundaries in all directions, 
preoperative finding; c) Intraoperative picture of the lesion removed 
by elliptical excision; d) Postoperative clinical picture of surgical 
defect closed by single interrupted sutures 
Discussion 
 
Antihypertensive drugs are the most common 
and widely used drugs among the population; 
however, according to very new data, they may be 
associated with an increased risk of melanoma 
occurrence [1]. As possibly potentiating the 
development of this type and another type of 
cutaneous tumours, different groups of drugs for the 
treatment of arterial hypertension are mentioned [1], 
[2], [5]. Studies of the carcinogenic effect of 
angiotensin receptor blockers (ARBs) predominate [2], 
[3], [4], [5], [5]. It is believed that this group of 
antihypertensive drugs generally carries a risk of 
developing cancer [4], but the individual risk of 
different agents is not yet known [4]. The prevailing 
number of data, however, is in the direction of 
claiming that ARBs are highly associated with 
melanoma development [2], [3], [5]. In vitro, 
experimental data show that losartan inhibits NHE1 
(Na + /H + exchanger isoform 1) activity and migration 
of human melanoma cells (MV3), but at the same time 
stimulates MV3 cell adhesion and invasion [3]. 
Some events in 2018 lead to important 
analyses and conclusions. In June 2018, US 
manufacturer Prinston Pharmaceuticals Inc. stopped 
producing products containing valsartan because it 
detected traces of N-nitrosodimethylamine (NDMA) in 
the active pharmaceutical ingredient of valsartan (API) 
provided by a Chinese manufacturer (Zhejiang Huahai 
Pharmaceutical Co) [6]. NDMA is defined as a 
chemical substance in the group of potent 
carcinogens and, according to the US Department of 
Health and Human Services, exposure to high doses 
of NDMA may cause liver damage [7], [8]. This is 
confirmed by animal studies that indicate that NDMA 
can cause tumours in the liver, kidneys and the 
respiratory tract, making it a likely human carcinogen 
[8]. Subsequently, the withdrawal of valsartan 
expands, following the detection of NDMA in drugs 
manufactured by a second Chinese manufacturer 
(Zhejiang Tianyu Pharmaceuticals of Taizhou) and by 
a manufacturer in India (Hetero Labs Limited, called 
Camber Pharmaceuticals), followed by voluntary 
withdrawal of valsartan products from several 
companies (Major Pharmaceuticals, Solco Healthcare 
and Teva Pharmaceuticals Industries, as well as 
valsartan/hydrochlorothiazide from Solco and Teva) 
[9], [10]. 
In September 2018, information about a 
second potential carcinogen in the product valsartan-
N-nitrosodiethylamine (NDEA) was published [11]. 
In November 2018, SciGen Pharmaceuticals 
voluntarily withdrew ARB-irbesartan due to NDEA 
content and according to the US Food and Drug 
Administration (FDA): „This is the first non-valsartan 
drug product the agency has found to contain the 
NDEA impurity" (Aurobindo Pharma Ltd manufactures 
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the active pharmaceutical ingredient (API) for 
ScieGen's irbesartan products) [12]. 
The case we have described supports the 
thesis that, in the presence of pigment lesion, 
irbesartan probably promotes carcinogenesis in the 
direction of cutaneous melanoma. This statement 
differs from that shared in other articles, according to 
which valsartan are a possible inducer of de novo 
melanomas, i.е., without the presence of precursor 
lesions. 
Also, the FDA shares the likelihood of cancer 
being dose-dependent (daily intake of the highest 
dose of valsartan (320 mg) throughout 4 years, 
1/8000 patients are likely to develop cancer) [13]. 
According to the EMA (European Medicines 
Agency) (as a result of an electronic correspondence), 
there have been 9 reported cases of melanoma in 
patients receiving valsartan. None of them has been 
formalised and suggestions remain as to whether 
products are contaminated with NDMA/NDEA, or it is 
possible that the carcinogenic effect comes directly 
from the generic substance of valsartan as well as 
from the presence of a potential another carcinogen 
[3], [11]. The same open question remains about the 
carcinogenic effect of irbesartan. 
According to a study of 2015, angiotensin II 
therapy potentiates melanogenesis (increases 
melanin content and increases tyrosinase activity) 
through angiotensin type 1 receptors, and losartan 
eliminates this effect [13]. This, however, indicates 
that ARBs directly affect melanogenesis and the 
carcinogenic effect may be related to another, 
unknown pathogenetic chain. 
In conclusion, the case presented is an 
interesting example due to 1) the possibility of 
Irbesartan induced cutaneous melanoma in the 
presence of precursor pigmented lesion and 2) the 
perfect therapeutic result due to perform one step 
melanoma surgery. 
The content of probable carcinogens, in 
representatives of the group of angiotensin receptor 
blockers, suggests the need for further studies on the 
individual carcinogenic risk for particular drugs. 
Interestingly, one of the most widely used drugs, i.e. 
the antihypertensive drugs and acetylsalicylic acid, 
are pointed out as probably triggering the 
development of melanoma. 
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